Actively Recruiting
Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
Led by Sun Yat-sen University · Updated on 2025-04-03
112
Participants Needed
10
Research Sites
202 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, randomized, controlled, multicenter, phase II clinical trial to evaluate the efficacy and safety of R-CMOP versus R-CHOP in the initial treatment of low-risk and medium-risk diffuse large B-cell lymphoma (DLBCL).
CONDITIONS
Official Title
Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 80 years, male or female
- Pathologically confirmed diffuse large B-cell lymphoma (DLBCL)
- No prior treatment for DLBCL
- At least one measurable or evaluable lesion meeting Lugano 2014 lymphoma criteria
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-
- Expected survival of 3 months or more
- International Prognostic Index (IPI) score of 2 or less
- Sufficient bone marrow, liver, and kidney function
You will not qualify if you...
- Other types of large B-cell lymphoma such as Primary Cutaneous Diffuse Large B-cell Lymphoma (Leg Type), Primary Mediastinal (Thymic) Large B-cell Lymphoma, Lymphomatoid Granulomatosis, ALK-positive Diffuse Large B-cell Lymphoma, Plasmablastic Lymphoma, Intravascular Large B-cell Lymphoma, T-cell/Histiocyte-rich Large B-cell Lymphoma, and others
- Transformed diffuse large B-cell lymphoma
- Central nervous system involvement or need for high-dose methotrexate prevention
- Previous antitumor therapy
- Infection with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)
- Pregnant or lactating women and subjects of childbearing age not willing to use contraception
- Mentally ill persons or those unable to provide informed consent
- Investigator judgment that the patient is not suitable for the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China
Not Yet Recruiting
2
Gansu Provincial Cancer Hospital
Lanzhou, Gansu, China
Not Yet Recruiting
3
The Fifth Affiliated Hospital of Guangzhou Medical University.
Guangzhou, Guangdong, China, 510060
Actively Recruiting
4
The Affiliated Hospital of Guangdong Medical University
Guangzhou, Guangdong, China
Not Yet Recruiting
5
Shenzhen People's Hospital
Shenzhen, Guangdong, China
Not Yet Recruiting
6
The Fifth Affiliated Hospital of Sun Yat-sen University
Zhuhai, Guangdong, China
Actively Recruiting
7
Guangxi Zhuang Autonomous Region Cancer Hospital
Guilin, Guangxi, China
Not Yet Recruiting
8
Ganzhou Cancer Hospital
Ganzhou, Jiangxi, China
Not Yet Recruiting
9
Jiangxi Provincial Cancer Hospital
Nanchang, Jiangxi, China
Not Yet Recruiting
10
Beijing Tongren Hospital
Beijing, China
Not Yet Recruiting
Research Team
Q
Qingqing Cai, MD. PhD.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here